Wickramasekara: Science is uniquely structured to benefit from LLM architectures
Sajith Wickramasekara · No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara · Nov 13, 2025 · at 32:40
Benchling CEO Sajith Wickramasekara discusses why leading frontier AI research labs are prioritizing life sciences and drug discovery.
0:00 / 0:48exact quote · 48.9s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I go back to that sort of returns to intelligence piece where I think science is a problem that has some shape to it that really benefits from the LLM architecture. Like you just think about the corpus of scientific literature as like this vast pool of unstructured text. And like, these are kind of, these are like roles where these are Pursuits where, like, that's a ton of domain knowledge to hold in your head, and there's so much specialization, and so the idea that, like, you could be, like, truly standing on the shoulders of giants, I think is very appealing of, I've got a scientist, and I'm in an early-stage biotech, and some, now I can have access to the world's best, like, clinical design expert, or the world's best toxicologist, or the best research assistant who can even, like, read papers better than me to figure things out. Like, there's a lot about science that, again, is so artisanal and inefficient that it seems like a problem that AI is going to be much better at.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Sajith Wickramasekara
Wickramasekara: Major pharma increasingly licenses drug molecules from China
“We've seen this huge uptick in pharma going to China and buying molecules that they typically would have bought from American biotechs.”
Wickramasekara: Clinical trial optimization is a red herring versus molecule quality
“People get very focused on clinical trials because they're like the biggest line item. And they're important, don't get me wrong, but I think it's actually a bit of a red, red herring. Where, ah, yes, there are operational problems. Like, some studies are desi…”
Wickramasekara: GLP-1s will probably be the best-selling drugs of all time
“And then all of a sudden, like we have this category defining medicine that's going to go on to probably be the best selling drug of all, all time.”
Wickramasekara: AI in scientific discovery will focus on augmentation over autonomy next 1-2 years
“While I would love for that to happen, and I'm maybe more optimistic on a longer time scale, we will get there. I think in the short term, I'm next one to two years, which, you know, already feels like an eternity in AI time. I'm a little bit more bullish on s…”
Wickramasekara: Most Biotech Researchers Are Not Yet Using Much AI in R&D
“Most people aren't really using that much AI and R&D yet. They all want to, they're primed to, but there's a lot of concerns about accuracy, IP, security, legal. And I think the farther you go from SF, the like, Larger those concerns, concerns get.”
Wickramasekara: Pure AI biology model companies must morph into biopharma
“I think it's unlikely, it's possible, but it's unlikely that sort of, hey, they're just gonna remain pure model companies who just do deals with pharma, where pharma, you know, pays them a hundred million dollars upfront or something like that, and they have f…”